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Clinical trials of primary axillary hyperhidrosis (AHH) require rigorous measurement of AHH 
severity from the patient’s perspective. Previously, we reported conceptualization and item 
content development for the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) 
scale.  
Objective 
To evaluate the psychometric performance and estimate clinically meaningful change scores for 
the HDSM-Ax in a Phase IIb clinical study of sofpironium bromide gel for AHH. 
Method  
HDSM-Ax measurement performance was analyzed in trial response data using two 
psychometric paradigms: Classical Test and Rasch Measurement Theories (CTT; RMT). HDSM-
Ax meaningful change scores were estimated from anchor-based methods using two global 
summary questions of hyperhidrosis severity and the Hyperhidrosis Disease Severity Score 
(HDSS). 
Results  
HDSM-Ax satisfied CTT and RMT criteria as a fit-for-purpose outcome measure in AHH 
clinical trials. Within-person anchor-based analyses indicated a 1-point change in HDSM-Ax 
severity score (range 0-4) represents a clinically meaningful change in AHH severity.     
Conclusion  
HDSM-Ax is a well-defined and reliable measure of AHH severity. A 1-point change in HDSM-
Ax score is clinically meaningful.   




Primary hyperhidrosis is a chronic disorder of excessive sweating that can profoundly 
impact quality of life. Measuring hyperhidrosis severity is challenging. The absence of widely 
accepted, scientifically sound, patient-reported outcome (PRO) measures hinders development of 
better hyperhidrosis treatments. 
The frequently used Hyperhidrosis Disease Severity Scale (HDSS) is a single question 
with four severity levels. Such “single-item” scales do not meet scientific and regulatory rigor as 
outcome measures because single questions cannot measure the extent of disease impact reliably, 
validly, or precisely.1,2 In addition, each HDSS response category combines two constructs: 
tolerability and impact on daily life. Thus, the HDSS does not allow patients to report different 
levels of effect for these two constructs. Quantitative axillary sweating measurements, such as 
gravimetric sweat production, are variable, difficult to interpret, and correlate poorly with patient 
experience.3,4 
Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) was developed to be an 
accurate, comprehensive measure of primary AHH severity satisfying scientific and regulatory 
requirements for treatment trials.1,3,5 Three planks underpin current PRO requirements: a clearly 
defined variable to measure, an explicit context of use, and robust measurement performance.1 
When these criteria are met, it is reasonable to interpreting scores and estimate clinically 
meaningful changes. 
Previously, we reported conceptualization and item content development for HDSM-Ax.6 
The result was an 11-item questionnaire with each item scored 0-4, yielding a total score of 0-44. 
HDSM-Ax was used as the primary efficacy endpoint in a randomized, controlled, double-
blinded, phase IIb study of sofpironium bromide gel for treatment of AHH (NCT03024255).6 We 
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now evaluate HDSM-Ax measurement performance and estimate clinically meaningful change 




The design of the phase IIb clinical study has been reported previously.6 In brief, adults 
(aged >18) with AHH were randomized (ratio 1:1:1:1) to 1 of 3 sofpironium bromide gel 
strengths (5%, 10%, or 15%) or vehicle, applied daily for 42 days. In total, 227 participants were 
enrolled at 23 clinical sites in the United States. Assessments were performed at 11 time-points: 
screening, baseline, and days 8, 15, 22, 29, 36, 41, 42, 43, 57. Measurements included: HDSM-
Ax, HDSS, and two global summary questions of hyperhidrosis severity.  
Protocols and procedures were approved by the Aspire Institutional Review Board 
(Santee, CA). All participants gave informed consent before any study-related procedures. The 
trial was conducted in accordance with the principles of Good Clinical Practice and the 
International Council on Harmonisation.  
 
HDSM-Ax: Evaluation of Performance and Clinically Meaningful Change  
First, we reviewed data availability (missing data at questionnaire- and item-levels) and 
item-response distributions. Next, we examined the measurement performance of HDSM-Ax 
using two complementary psychometric approaches (paradigms): traditional psychometric 
methods based on Classical Test Theory (CTT) and modern psychometric methods based on 
Rasch Measurement Theory (RMT).7-9 Data analyses were performed using Microsoft EXCEL, 
IBM SPSS Statistics 22, Rasch Unidimensional Measurement Model Professional Edition.10  
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We estimated HDSM-Ax meaningful change scores using triangulated data from three 
anchor variables: two global summary questions of hyperhidrosis severity, and the HDSS.11 
These analyses assume a 1-point change in any anchor variable is clinically meaningful. We 
computed estimates of clinically meaningful change in HDMS-Ax score using HDSM-Ax 
changes from baseline to end-of-treatment. Specifically, we: 1) grouped participants according to 
their integer change in each anchor variable; 2) computed HDSM-Ax mean-change scores for 
each integer-change group; 3) computed HDSM-Ax mean-change score for each 1-point change 
on each anchor variable; and 4) averaged those HDSM-Ax mean-change scores to give a single 
estimate of the HDSM-Ax mean-change score that corresponded to a clinically meaningful 
change in the anchor variable. 
 
Results 
Table 1 shows demographic and baseline characteristics of the 225 participants receiving 
treatment with sofpironium bromide or vehicle. Two additional participants were enrolled but 
did not receive treatment. Participant characteristics were similar across the four randomized 
groups. The HDSM-Ax was administered on 2325 occasions. Complete data were available for 
2321 (99.83%) occasions (Table 2). The high rate of completions implies participants considered 
all HDSM-Ax items clinically relevant and comprehensible. Item responses were well-
distributed across categories (Table 2), implying all categories were clinically relevant. 
 
 
CTT Evaluation of HDSM-Ax Measurement Performance  
Table 3 summarizes the CTT evaluation.  
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Scaling assumptions: HDSM-Ax scale scores could be computed for all participants at all 
time points. Item mean scores and variances spanned a narrow range; item total correlations 
exceeded the required minimum of 0.30.12 Factor analytic studies identified one factor. These 
findings satisfy CTT criteria for summing the 11 item scores without weighting or 
standardization, to generate an HDSM-Ax total score. 
Scale-to-sample targeting: Good scale-to-sample targeting was indicated by 1) HDSM-
Ax total scores spanning the entire scale range, 2) mean scores located near the scale midpoint, 
3) small floor and ceiling effects, 4) skewness between +/-1.0 (-0.278). 
Reliability: High Cronbach’s alpha (0.985) and homogeneity coefficients (0.859) indicate 
good internal consistency. Test-retest reproducibility correlations, from baseline and screening 
scores, appeared low (r=0.543). Additional analyses suggested this was artefactual: HDSM-Ax 
score ranges were narrow at screening and baseline due to the study’s inclusion criterion 
(HDSM-Ax score 3 or 4). Paired sample t-tests indicated small, non-significant numeric 
differences between screening and baseline scores.   
Validity:  Convergent and discriminant construct validity was supported by the direction, 
magnitude, and pattern of HDSM-Ax total score correlations with independent variables. Group 
differences construct validity was supported by stepwise decreases in HDSM-Ax mean scores 
associated with decreasing global summary questions and HDSS scores. 
Ability to detect change: The ability of HDSM-Ax to detect change in AHH severity was 
supported by change scores consistent with study hypotheses (means and effect sizes): 1) 
differences from screening to baseline were small and non-significant, 2) changes from baseline 
to end-of-treatment were large, and 3) changes from baseline to end-of-treatment in participants 
receiving active treatment exceeded those in vehicle-treated participants. 




RMT Evaluation of HDSM-Ax Measurement Performance  
Table 4 numerically summarizes the RMT evaluations. 
Scale-to-sample targeting: Figure 1A (and Table 4) shows HDSM-Ax-derived interval 
measurements of participant hyperhidrosis (person-measures, upper histogram) are distributed 
over a wide range (17.152 logits [log-odds units]) and span the distribution of HDSM-Ax item 
threshold locations (lower histogram). These results indicate this sample is well-suited for 
analyzing HDSM-Ax item and scale performance. 
Item and scale performance: Figure 1B (and Table 4) show HDSM-Ax items formed an 
ordered continuum on which AHH severity could be measured. The thresholds (points of 
transition between adjacent item response categories) were ordered in the response data as 
intended conceptually, indicating that higher HDSM-Ax item and total scores indicate greater 
AHH severity. Table 4 shows HDSM-Ax items provided good measurement precision, were a 
statistically cohesive set, were free from scoring bias, and were stable across different time-
points and treatment groups. These findings indicate good item and scale performance and—
combined with good scale-to-sample targeting—indicate participant and sample HDSM-Ax 
results can be studied and interpreted as intended. 
Individual person and group measurement: Table 4 shows a high person separation index 
indicating the HDSM-Ax effectively separated this sample in terms of participant AHH severity. 
In 93.3% of HDSM-Ax completions, participant response patterns across the 11 items were 
consistent with expectation rather than random. Measurement error associated with person 
measurements was small across a wide range indicating precise measurement. 
 




Meaningful Change Estimation 
Table 5 shows HDSM-Ax mean change scores corresponding with 1-point changes in 
each anchor variable. Since the HDSM-Ax mean change estimates are computed from samples 
of varying sizes (1-78), we report estimates using different sample size cut-offs. The grand mean 
of these values is approximately 20 points (in CTT 0-100 score range metric). This equates to 1 
point on a 0-4 average item-level score range metric. 
 
Discussion 
The HDSM-Ax PRO satisfied both CTT and RMT criteria as a fit-for-purpose measure. 
Although clinicians are far more familiar with CTT analyses and results, CTT has significant 
scientific weaknesses.13 In contrast, RMT provides stronger evaluations of measurement 
performance.14,15 Adequate PRO measurement performance enabled meaningful interpretation of 
scores and score changes, as well as estimation of meaningful changes. Our analyses imply a 
change in HDSM-Ax total score of 1 point (on a scale of 0-4) represents a clinically meaningful 
shift in AHH severity.  
Although RMT identified some departures from model expectations—for example small 
degrees of misfit—these departures were not considered of substantive importance. RMT 
analyses will always identify some abnormalities because discrete integer-level questionnaire 
response data are tested against a mathematic model. Moreover, the relationship between ordinal 
HDSM-Ax total scores derived from CTT and HDSM-Ax interval measures derived by RMT 
was nearly linear over much of its range (Fig 1C). This implies HDSM-Ax total score can be 
analyzed as interval measures. 
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HDSM-Ax total scores correlated highly with both global questions and HDSS (r=0.79 – 
0.91; not shown). This may suggest single-item measures could be suitable for clinical trials. 
However, single-item scales try to encapsulate complex clinical constructs in one question. By 
definition therefore, single-item scales lack validity to adequately represent construct content.  
Some HDSM-Ax item pairs were highly correlated, suggesting possible redundancy. 
However, during development of HDSM-Ax, patient-centered qualitative analysis found all 
items addressed related but distinct and important AHH issues.5 Our quantitative analyses show 
highly correlated HDSM-Ax items have different distributions and variances (available on 
request), further supporting the conclusion that each item provides unique information.  
 
Limitations 
Assessment of clinically meaningful change relied on anchor variables that were single-
item measures. These are considered scientifically limited. Nevertheless, at this time, this 
approach is recommended for determining clinically meaningful change.11 
 
CONCLUSION 
This study of the HDSM-Ax, together with its previously reported conceptualization and 
item content development,5 support its use as a fit-for-purpose measure of AHH severity in 
clinical trials. We expect use of the HDSM-Ax will improve assessment of true treatment effects 
in comparison to pre-existing scales, such as HDSS. The current analyses imply a change of ≥1 
point in within-person HDSM-Ax score is clinically meaningful (on a scale of 0-4).  
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Figure 1. RMT analyses. (A) Scale-to-sample targeting showing person-measure distribution 
(upper histogram) and item-threshold distribution (lower histogram). (B) Threshold map in order 
of AHH severity. A higher score on each item indicates more self-reported observations with 
hyperhidrosis. (C) HDSM-Ax ordinal total scores derived by CTT on a scale of 0-44 (y-axis) 
versus HDSM-Ax linear measures of hyperhidrosis severity derived by RMT (x-axis).   
 




















































































Table 1: Sample Characteristics 
 
  Randomization group 





gel 5% 10% 15% 
n 227* 57 57 57 56** 
Female, n (%) 102 (45) 30 (53) 25 (44) 22 (39) 25 (46) 





Baseline values      
HDSM-Ax score (0-4), 
mean (SD) 






HDSS score (1-4), 
mean (SD) 
















No. (%) completing study 196 (86.3) 52(91.2) 50 (87.7) 49 (86.0) 45 (80.4) 
*The randomized sample comprised 227 participants whereas the modified intent-to-treat sample, which included all 
participants who were randomized and received study drug, comprised 225 participants.  
**Two participants were randomized to receive sofpironium bromide gel 15% but were not dispensed the 
medication. 
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Table 2: HDSM-Ax, Global Questions and HDSS Response Distributions 
HDSM-Ax Item HDSM-Ax Item Sore   
Code Statement 0 1 2 3 4 Total Missing 
  
None of the 
time 
A little Some Most 
All of the 
time 
  
Q01A Damp or wet clothing because of your underarm sweating 161 426 623 707 408 2325 0 




Mild Moderate Severe Very severe   
Q02A Underarm sweating when you felt nervous, stressed or anxious 212 379 581 637 516 2325 0 
Q02B Damp or wet clothing because of your underarm sweating 178 420 615 656 456 2325 0 
Q02C Underarm sweating after little or no physical exercise 199 462 608 679 377 2325 0 
Q02D Underarm wetness 170 452 611 666 426 2325 0 
Q02E Underarm sweating for no apparent reason 263 433 560 677 392 2325 0 
Q02F Underarm sweating that was manageable 398 394 581 601 351 2325 0 
Q02G Underarm sweating when you were cool 315 488 615 665 239 2322 3 
  Not at all Slight Moderate Strong Very strong   
Q03A Feeling the need to change clothes because of your underarm sweating 437 352 512 591 433 2325 0 
Q03B Feeling the need to wipe the sweat from under your arms 354 410 503 555 503 2325 0 
         
 Anchor Variables        
  
None of the 
time 
A little Some Most 





Since yesterday, how much time did you experience excessive underarm sweating 230 439 627 819 210 2325 0 
  None Mild Moderate Severe Very severe   
Global 
Q2 
How severe was your underarm sweating AT ITS WORST since you woke up 
yesterday 
122 496 579 735 393 2325 0 






Intolerable   
HDSS* How would you rate the severity of your hyperhidrosis for the past week N/A 226 848 824 426 2324 1 
*The full wording of the four HDSS responses are shown on the x axis of Figure 1A. 
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Table 3: HDSM-Ax Evaluation Using CTT Analyses 
 
CTT Psychometric property Value 
Scaling assumptions^  
Item mean scores, range  2.010 – 2.373  
Item variances, range  1.357 – 1.893  
Item total correlations corrected for overlap, range  0.860 – 0.941  
Factor analytic studies (principal components analysis)  
No. components extracted with Eigenvalues > 1.0 1 
No. components extracted explaining >5% of total variance 1 
1st component Eigenvalue (% total variance explained)  9.597 (87.2) 
2nd component Eigenvalue (% total variance explained) 0.242 (2.2) 
  
Scale-to-sample targeting  
Scale range 0-44 (default metric) 
Possible scale range (mid-point)  0-44 (22)  
Observed score range  0-44  
Mean (SD)  24.46 (12.79)  
Median (IQR)  25 (14-35)  
Scale range 0-100 (transformed metric)  
Possible scale range (mid-point) 0-100 (50) 
Observed score range 0-100 
Mean (SD) 55.58 (29.06) 
Median (IQR) 56.82 (31.82 – 79.55) 
Range independent statistics  
Ceiling effect (score=0): n (%)  82 (3.5)  
Floor effect (score=44 or 100): n (%)  102 (4.4)  




Cronbach’s alpha^  0.985  
Homogeneity coefficient^  0.859  
Test-retest reproducibility*  
Correlation between screening and baseline scores  0.543 (n=227)  
Difference between screening and baseline scores (0-100 metric):  
Paired samples t-test: Mean; SD (t-value; p-value)  
SRM^^; CES**  
 
-0.61; 8.37 (-1.10; 0.273) 
-0.073; -0.068  
Standard error of measurement (SEM)^*  
SEM (SD√(1-reliability)) [+/-1.96 SEM] {default range} 1.566 [+/- 3.07] 
SEM (SD√(1-reliability)) [1.96 SEM] {0-100 metric} 3.559 [+/- 6.976] 
  
Validity 
Convergent and discriminant construct validity (HDSM-Ax correlations a with) 
HDSS  +0.79   
Global summary question 1 (n=2325)  +0.91  
Global summary question 2 (n=2325) +0.89  
Gravimetrically Measured Sweat Production (bilateral) (n=2319) +0.39  
Group differences construct validity  
Sample with each HDSS score HDSM-Ax mean score 
1=Sweating never noticeable, never interferes with daily activities (n=226) 10.267 
2=Sweating tolerable, sometimes interferes with my daily activities (n=848) 38.114 
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3=Sweating barely tolerable, frequently interferes with daily activities (n=824) 70.741 
4=Sweating intolerable always interferes with my daily activities (n=426) 85.003 
ANOVA: F(p)[df] 2262.085 (0.000) [4; 2320] 
Sample with each Global summary question 1 score HDSM-Ax mean score 
0=None of the time (n=230) 6.957 
1=A little of the time (n=439) 26.532 
2=Some of the time (n=627) 51.439 
3=Most of the time (n=819) 78.424 
4=All of the time (n=210) 92.857 
ANOVA: F(p)[df] 2998.355 (0.000) [4; 2320] 
Sample with each Global summary question 2 score HDSM-Ax mean score 
0=I did not have underarm sweating (n=122) 3.111 
1=I had underarm sweating but it was mild (n=496) 22.888 
2=I had underarm sweating and it was moderate (n=579) 48.866 
3=I had underarm sweating and it was severe (n=735) 74.380 
4=I had underarm sweating and it was very severe (n=393) 87.875 
ANOVA: F(p)[df] 2262.085 (0.000) [4; 2320] 
  
Ability to detect change  
Screening to baseline (n=227; computed as screening minus baseline)  
Paired samples t-test: t-value (p-value)  -1.10 (0.273) 
Cohen’s ES (mean change / SD screening)  -0.068 ((-0.61 /8.94) 
SRM (mean change / SD change)  -0.073 (-0.61 / 8.37) 
Baseline to Day 42 (n=201; computed as baseline minus Day 42)  
Paired samples t-test: t-value (p-value)  t=8.045 (p<0.001)  
SRM (mean change / SD change)  1.82 (48.46 / 26.69)  
^Computed from 2321/2325 with complete data; 
*Agreement between total scores at screening and baseline; 
^^ SRM=Standardised Response Mean = mean change / SD change; 
** Cohen’s ES = Cohen’s Effect Size = Mean change / SD screening (8.9381); 
^* Estimate of the error range for an individual person’s HDSM-Ax total score; 
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Table 4. HDSM-Ax Evaluation Using RMT Analyses  
   
RMT Psychometric property Value 
SCALE-TO-SAMPLE TARGETING  
Item locations  
Item location range (logit span) -0.682 to +1.031 (1.713) 
Threshold location range (logit span) -6.982 to +6.797 (13.779) 
Person locations  
Person measure range (logit span)  -8.757 to +8.395 (17.152) 
Person measure mean (SD) 0.833 (4.467) 
No. extreme scores: n (%) 184 (7.91) 
Floor/ceiling effect: n (%)* 102 (4.4) /82 (3.5) 
  
ITEM & SCALE PERFORMANCE  
Thresholds  
No. items with disordered thresholds 0 of 11 
Measurement precision  
No. logits / threshold  0.313 
Item fit statistics  
Item-person interaction (n=2141)  
Item fit residuals - range -12.163 to +14.604 
Item fit residuals exceeding +/-2.5 (item) 9 (n=7, <-2.5; n=2, >+2.5) 
Random sample of n=500  
Item fit residuals – range [random sample of n500] -6.421 to +5.678 
Item fit residuals exceeding +/-2.5 (item)  6 (n4<-2.5; n2>+2.5) 
Item-trait interaction  
Chi square values - range 8.850 to 105.240 
No. significant chi square values^ 3 
Sample size adjusted to n500  
Chi square values - range 2.067 to 24.577 
No. significant chi square values^   0 
Item bias  
No. of residual correlation^^ 55 
Range of item residual correlations -0.216 to +0.224 
No. correlations > +/-0.30; 0.40; 0.50 0, 0, 0 
Differential item functioning (DIF)  
No. items showing DIF by visit*^ 1 of 11 (item 1a) 
No. items showing DIF by treatment 0 of 11 
PERSON & GROUP MEASUREMENT  
Sample separation by these items  
Person separation index (reliability)** 0.976**(0.976***) 
Person fit statistics  
Person fit residuals, range -5.966 to +6.0443 
Person fit residuals exceeding +/-2.5: n (%) 347/2141 (16.2) 
Person fit residuals: <-2.5 / >+2.5 295^^^(13.78%) / 52 (2.43) 
*: where floor effect = MAX possible score (worst hyperhidrosis); ceiling effect = MIN possible score (least 
hyperhidrosis); 
^: with Bonferroni adjustment (0.000909 for 11 items) 
*^: DIF by visit is scale test-retest reliability 
**: with n=184 extreme scores included 
***: with extreme scores excluded 
^^: Where number of correlations is given by the combination rule, nCr=n!/[(n-r)!r!]) 
^^^: Most of these 295 values (191/295 = 64.75%) were due to people giving the same score to all 11 items. These 
response patterns are consistent but show up as “misfit”. 
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Table 5: Computation of HDSM-Ax Meaningful Change Estimates 
 
Anchor variable change score, sample size, 
HDSM-Ax mean change$ 






change score All n>20 n>30 n>40 
-4 8 -89.49     
-3 48 -73.44 16.05^    
-2 68 -55.48 17.96 17.96 17.96 17.96 
-1 40 -33.07 22.41 22.41 22.41 22.41 
0 31 -13.49 19.58 19.58 19.58  
1 6 2.27 15.76    




    
-4 6 -85.23     
-3 43 -71.99 13.24    
-2 75 -57.3 14.69 14.69 14.69 14.69 
-1 39 -34.73 22.57 22.57 22.57 22.57 
0 33 -13.43 21.3 21.3 21.3  
1 5 -7.73 5.7    
     Average 15.50 19.52 19.52 18.63 
HDSS change score n Mean     
-3 12 -78.98     
-2 74 -62.41 16.57    
-1 78 -42.07 20.34 20.34 20.34 20.34 
0 36 -25.19 16.88 16.88 16.88  
1 1 13.64 38.83    
  Average 23.16 18.61 18.61 20.34 
       
  Grand mean* 19.00 19.37 19.37 19.72 
$: Computed using CTT HDSM-Ax total score 0-100 metric 
^: Computed as: 16.05 =  (-73.44) – (-89.49) 
*: Grand mean is the average of the three bolded averages in each column (e.g. 19.00 = (18.35+15.50+ 23.16) / 3)  
 
 
 
 
 
 
 
